Search Orphan Drug Designations and Approvals
-
| Generic Name: | Paclitaxel | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Taxol | ||||||||||||||||
| Date Designated: | 03/25/1997 | ||||||||||||||||
| Orphan Designation: | Treatment of AIDS-related Kaposi's sarcoma. | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, Connecticut 06492 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | Paclitaxel |
|---|---|---|
| Trade Name: | Taxol | |
| Marketing Approval Date: | 08/04/1997 | |
| Approved Labeled Indication: | For the second line treatment of AIDS-related Kaposi's sarcoma. | |
| Exclusivity End Date: | 08/04/2004 | |
| Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







